reports
Regulus Therapeutics Inc: 2 directors
Two Directors at Regulus Therapeutics Inc bought 69,610 shares at between 1.060USD and 1.085USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Comm...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ: RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to: http://ww...
RGLS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc. (NASDAQ:RGLS) securities between January 21, 2016 and June 27, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/regulus-therapeutics. There is no cost or obligation to you. According to the complaint, throughout the class period, Defendants made false and/or misleading...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has C...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ: RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to: http://ww...
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadli...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Regulus Therapeutics Inc. (Nasdaq: RGLS) (“Regulus” or the “Company”) securities during the period between January 21, 2016 and June 27, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 3, 201...
RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Invest...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc. (NASDAQ:RGLS) securities between January 21, 2016 and June 27, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/regulus-therapeutics. There is no cost or obligation to you. According to the complaint, throughout the class period, Defendants made false and/or misleading...
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Regulus Therapeutics Inc. (Nasdaq: RGLS) (“Regulus” or the “Company”) securities during the period between January 21, 2016 and June 27, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 3, 201...
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Act...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS). Investors who purchased or otherwise acquired Regulus shares between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esqu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.